Tolerance and Efficacy of a Dermocosmetic Containing Neurosensine
dermocosmetic
eyelid eczema
periorbital skin
sensitive skin
Journal
Clinical, cosmetic and investigational dermatology
ISSN: 1178-7015
Titre abrégé: Clin Cosmet Investig Dermatol
Pays: New Zealand
ID NLM: 101543449
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
10
2022
accepted:
10
01
2023
entrez:
30
1
2023
pubmed:
31
1
2023
medline:
31
1
2023
Statut:
epublish
Résumé
Eyelid eczema (EE) is frequently observed in patients with an allergic or atopic diathesis. As for atopic eczema, restoring the skin barrier of the periocular region together with relieving clinical signs and symptoms is important in the management of EE. This study assessed the benefit and tolerance of a dedicated dermocosmetic (DC) in subjects with EE. Open-label study in adults with EE and sensitive skin. The DC was applied twice daily for 28 days. Dermatological signs (eczema, desquamation/dryness, erythema, swelling, roughness) and symptoms (itching, prickling, heat/burning sensation, tightness) on the periorbital region, as well as ophthalmological evaluation were assessed at Day 0, 14 and 28. Subjects assessed quality of life (QOL) using DLQI, the perceived benefit and cosmetic acceptability of the DC. Overall, 41 subjects were included; 59% were women. The mean age was 52.4±15.8 years; all subjects had periorbital sensitive skin. The DC immediately reduced the intensity of itching, prickling, heat/burning sensation and tightness. Clinical signs and symptoms had all significantly (p<0.001) improved by Day 14 and were sustained to Day 28. The DC significantly (p<0.001) improved the perception of irritation (73%) and swelling (66%) while soothing (59%) the periorbital skin regions at Day 28. QOL had improved at Day 28 (0.82±1.0) compared to Day 0 (4.17±2.23). No local adverse reactions were reported. Ophthalmological examinations paralleled the excellent dermatological tolerance of DC. The tested DC is highly efficacious in reducing clinical signs and symptoms of eyelid eczema and was well tolerated. NCT05540496.
Sections du résumé
Background
UNASSIGNED
Eyelid eczema (EE) is frequently observed in patients with an allergic or atopic diathesis. As for atopic eczema, restoring the skin barrier of the periocular region together with relieving clinical signs and symptoms is important in the management of EE. This study assessed the benefit and tolerance of a dedicated dermocosmetic (DC) in subjects with EE.
Materials and Methods
UNASSIGNED
Open-label study in adults with EE and sensitive skin. The DC was applied twice daily for 28 days. Dermatological signs (eczema, desquamation/dryness, erythema, swelling, roughness) and symptoms (itching, prickling, heat/burning sensation, tightness) on the periorbital region, as well as ophthalmological evaluation were assessed at Day 0, 14 and 28. Subjects assessed quality of life (QOL) using DLQI, the perceived benefit and cosmetic acceptability of the DC.
Results
UNASSIGNED
Overall, 41 subjects were included; 59% were women. The mean age was 52.4±15.8 years; all subjects had periorbital sensitive skin. The DC immediately reduced the intensity of itching, prickling, heat/burning sensation and tightness. Clinical signs and symptoms had all significantly (p<0.001) improved by Day 14 and were sustained to Day 28. The DC significantly (p<0.001) improved the perception of irritation (73%) and swelling (66%) while soothing (59%) the periorbital skin regions at Day 28. QOL had improved at Day 28 (0.82±1.0) compared to Day 0 (4.17±2.23). No local adverse reactions were reported. Ophthalmological examinations paralleled the excellent dermatological tolerance of DC.
Discussion
UNASSIGNED
The tested DC is highly efficacious in reducing clinical signs and symptoms of eyelid eczema and was well tolerated.
ClinicalTrialsgov Identifier
UNASSIGNED
NCT05540496.
Identifiants
pubmed: 36711070
doi: 10.2147/CCID.S391890
pii: 391890
pmc: PMC9880017
doi:
Banques de données
ClinicalTrials.gov
['NCT05540496']
Types de publication
Case Reports
Clinical Trial
Langues
eng
Pagination
161-165Informations de copyright
© 2023 Tan et al.
Déclaration de conflit d'intérêts
AD, GLD, ClF and DK are employees of La Roche-Posay Laboratoire Dermatologique. JT reports personal fees from La Roche-Posay Laboratoire Dermatologique, Laboratoire Vichy and CeraVe, outside the submitted work. The authors report no other conflicts of interest in this work.
Références
Contact Dermatitis. 2019 May;80(5):291-297
pubmed: 30629291
Int J Cosmet Sci. 2022 Feb;44(1):56-73
pubmed: 34813665
Klin Monbl Augenheilkd. 2005 Nov;222(11):853-5
pubmed: 16308815
Br J Dermatol. 2008 Sep;159(4):858-63
pubmed: 18721191
J Dtsch Dermatol Ges. 2010 Mar;8(3):159-66
pubmed: 19751221
J Drugs Dermatol. 2014 Nov;13(11):1365-72
pubmed: 25607704
Int J Cosmet Sci. 2013 Feb;35(1):2-8
pubmed: 22928591
Immunol Allergy Clin North Am. 2005 Aug;25(3):557-80
pubmed: 16054543
Am J Contact Dermat. 1996 Jun;7(2):65-76
pubmed: 8796745
Clin Rev Allergy Immunol. 2019 Feb;56(1):119-128
pubmed: 30421329
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
Contact Dermatitis. 2006 Nov;55(5):280-5
pubmed: 17026693
Antioxidants (Basel). 2021 Aug 21;10(8):
pubmed: 34439563
Clin Cosmet Investig Dermatol. 2015 Sep 15;8:479-83
pubmed: 26396539
Hautarzt. 2004 Jul;55(7):677-87; quiz 688
pubmed: 15197462
Clin Dermatol. 2014 Jan-Feb;32(1):131-40
pubmed: 24314387